Jan 12, 2022 / 02:45PM GMT
James Daniel Gordon - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, and good afternoon. I'm James Gordon, JPMorgan European Pharma and Biotech Analyst. And today, at the JPMorgan conference, I've got the pleasure of introducing the Hikma presentation and Q&A. And we've got Hikma, CEO, Sigurdur, joining us for his 20-minute presentation, and then we can have a 20-minute Q&A afterwards in the same room. So with that said, thanks a lot for joining us today, Siggi, I'm looking forward to the presentation.
Sigurdur Oli Olafsson - Hikma Pharmaceuticals PLC - CEO & Executive Director
Thanks, James, and good morning, good afternoon, everybody. Firstly, I'm sorry not to be -- being having this meeting in person, certainly missed the bus in San Francisco. I don't miss the queues at the elevators in the hotel in San Francisco. But hopefully, next year, we can do this together in person. I just need to remind you of the disclaimer on Slide 2.
But if we move to Slide 3, it's almost 4 years since I joined Hikma. And I'm really
Hikma Pharmaceuticals PLC at JPMorgan Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot